Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
China Isotope Radiation Corporation
1763China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; urea breath test kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Other Businesses segment provides independent clinical laboratory services for nuclear technology industry applications and medical product applications; and sells radiation therapy equipment and other miscellaneous services. In addition, the company engages in the production and sale of bio-pharmaceuticals. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation. Address: No. 66 Changwa Middle Street, Beijing, China
Analytics
Preço Alvo de Wall Street
261.38 HKDRácio P/E
7.79Rendimento de dividendos
7.23 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 1763
Análise de Dividendos 1763
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Crescimento de dividendos em 5 anos
428.00 %Crescimento contínuo
5 anosTaxa de pagamento em média de 5 anos
36.00 %Histórico de Dividendos 1763
Avaliação de ações 1763
Relatório 1763
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |